The findings were powerful enough that Mitchell believes they not only could mean that MDMA will become a frontline treatment for PTSD, but that similar drugs could emerge with their own therapeutic value. “My hope is that this will open the door to testing other psychedelic compounds for other conditions—such as LSD for alcohol use disorder and psilocybin for OCD [obsessive-compulsive disorder] and end-of-life distress,” she says.
Originally appearing here. (Archive)
“I speculate that the demand will be unprecedented,” says Jennifer Mitchell, Ph.D., lead author of the study. “There are so many people suffering from PTSD and the current treatment options leave much to be desired.”
Originally appearing here.